a Background: In some countries, HIV surveillance is based on case-reporting of newly diagnosed infections. We present a new back-projection method for estimating HIVincidence trends using individuals' CD4 þ cell counts at diagnosis.
Introduction
Public health surveillance systems provide information about the state of epidemics, informing decision-making around prevention, and clinical responses and impact evaluations of interventions. In most high-income countries, routine surveillance for HIV is based on case-reporting of all new HIV diagnoses. However, these surveillance practices imprecisely capture changes in HIV-incidence patterns due to the time lag between infection and diagnosis. Incidence is a critical measure for making up-to-date public health decisions, but it is difficult to capture accurately. Direct observation of incidence through ongoing cohort studies is infeasible for population-wide estimates, especially in low-incidence countries, as a large number of observations are necessary to provide sufficient accuracy. Cohort studies of at-risk groups can reduce the number of observations necessary, but continual recruitment to such studies is expensive to maintain and may not be representative of the general population. Most high-income countries base epidemic assessments on numbers of diagnoses, sometimes accompanied by statistical back-projection methods that estimate population incidence. In countries that base their population HIV surveillance on case notification, data are collected on factors such as demography, likely route of HIV acquisition, and CD4 þ cell count. CD4 þ cell count is collected because it provides an indication of progression in disease and thus also eligibility to initiate antiretroviral therapy (ART). Although CD4 þ measurements vary between and within individuals [1, 2] , because they provide indications of disease progression, they can be used to estimate a range in likely time from infection to diagnosis. We posit that applying this concept to surveillance data in populations can provide estimates of distributions of time from infection to diagnosis across all diagnosed cases, from which trends in population incidence can also be inferred.
The Working Group on Estimation of HIV Prevalence in Europe produced a review paper of methods [3] [4] [5] [6] [7] [8] [9] that combine diagnosis data with additional information such as disease progression and testing rates to estimate the incidence and number of people living with undiagnosed HIV [10] . Some of these methods have been complicated over time by the introduction of ARTwhich has changed the expected disease history of people living with HIV (PLHIV), whereas new tests such as incidence assays and the routine measurement of CD4 þ cell counts have improved the available data.
CD4
þ cell counts at diagnosis have previously informed estimates of HIV incidence in England and Wales through their use in mathematical models [11, 12] . These multistate compartmental models classify the population of PLHIV into bands of CD4 þ cell counts, and use Bayesian methods to calculate probabilistic transfer between bands of CD4 þ cell counts and the probability of diagnosis. Other methods have used CD4
þ cell count at diagnosis and simultaneous HIV/AIDS diagnosis to estimate the number of people with undiagnosed HIV infections [13] .
Here, we describe a novel method to infer the time between infection and diagnosis for individuals based on CD4 þ cell count at diagnosis. We apply the method to data from Australia's National HIV Registry to estimate population incidence. Our approach differs from the previous approaches because it calculates the continuous expected decline and variability in CD4 þ cell count within individuals in the population using results from observational studies, including starting CD4 þ cell count, CD4 þ decline, and within-individual CD4 þ variability. This method not only provides estimates for incidence but also estimates for average time between infection and diagnosis, annual testing rates in the population, the total number of undiagnosed people, and associated uncertainties in these measures.
Methods

Data source
We demonstrated our back-projection methodology using diagnosis data from the Australian National HIV Registry [14] , which contains data for all 35 286 individuals diagnosed with HIV in Australia up to 31 December 2013. Of these records, 16 568 had CD4
þ cell counts at diagnosis (taken within 3 months of diagnosis), with increasing testing and reporting over time such that the vast majority of cases in recent years have an associated CD4 þ cell count around diagnosis. Missing CD4 þ cell counts at diagnosis were imputed using Markov Chain Monte Carlo multiple imputation over the variables of sex, year of diagnosis, age, and square root CD4
þ cell count at diagnosis. A total of 18 718 (53%) CD4 þ cell counts were imputed, with 9882 CD4 þ cell counts (93.1%) for the 10 614 diagnoses prior to 1990. CD4 þ cell counts were recorded in 82% of cases after 2000. We excluded 1226 people who were previously diagnosed overseas, leaving 34 060 local diagnoses. Multiple reporting of the same diagnosis is accounted for by using a method proposed by Larsen [15] , in which the number of unique birthdates are used to estimate the expected number of diagnoses of people born in that year. This method has been used previously to account for multiple reporting in Australia [16] . We estimated that 3113 of the local diagnoses were duplicates, leaving 30 947 diagnoses for the calculation of incidence in Australia.
Simulation overview
To back-project incidence from diagnoses, we used the following variables: evidence of previous HIV-negative date, indeterminate western blot, recent illness indicating seroconversion sickness, CD4
þ cell count at diagnosis, and date of diagnosis. To estimate the time between infection and diagnosis, we simulated CD4 þ cell count change among treatment-naive PLHIV.
Simulating CD4
R progression within individuals In the simulation, CD4 þ cell counts start from a HIVuninfected CD4 þ distribution. From a variety of reported CD4 þ cell count distributions [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , we created a bootstrapped dataset through simulation and random resampling (weighted according to the study sample size). We used the median and SD of the log-normal distribution of this bootstrapped data for our simulations of CD4 þ decline.
Following infection, CD4 þ cell count rapidly declined to a median of 418 cells/ml at day 17 [34] and subsequently rebounded to a median of 636 (95% uncertainty bound 586-686) at day 40 during the primary infection stage [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (see Appendices 2 and 3 for justifications, http:// links.lww.com/QAD/A690). The simulated CD4 þ progression then followed a square root decline of 1.6 square root cells/ml (95% uncertainty bound 1.4-1.8) per year [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] until the CD4 þ cell count reached an average of 61 cells/ml, from which point the decline progressed linearly (see Appendix 4 for justifications, http://links.lww.com/QAD/A690). CD4 þ cell counts of individuals between measurements can vary greatly [2, 48] . We incorporated variability in the measured CD4
þ cell count about the expected mean for the individual at that point in time using the equation from Hughes et al. þ cell count at that point of time in the log e scale [49] ). This accounts for individual variability in repeated CD4 þ measurements.
Estimation of average testing rate
We generated a sample population by simulating CD4 þ cell count decline with time and applying an annual testing probability, which increases exponentially as CD4 þ cell counts approach zero due to symptomatic presentation (the rate of change in testing rate with CD4 þ cell count is fitted to data in the registry). The testing probability applied to the simulated population is adjusted until the distribution of the CD4 þ cell count at diagnosis of the simulated sample population matches the distribution of the CD4 þ cell count at diagnosis of the empirical diagnosis data of the HIV Registry. This optimization method is repeated for 200 different parameterizations (based on uncertainty in the parameter estimates) and for each year in the simulation to account for stochastic variability and changes in testing patterns over time.
Selecting time of infection for each diagnosis
To estimate the time since infection for each individual diagnosis in the Australian National HIV Registry, the model matches the CD4 þ cell count at diagnosis with simulated CD4 þ cell count declines. For example, if an individual has a CD4 þ cell count of 350 cells/ml at diagnosis, then the model randomly selects a simulated CD4 þ cell count at diagnosis from our set of simulations, with CD4
þ cell counts at diagnosis of 350 AE 10 cells/ml. The time until diagnosis of the selected simulation is then the estimated time until diagnosis of the diagnosed individual. This linking process occurs for each of the 200 parameterizations.
Additional adjustments due to data acquired in recent years
Individual data recording recent indeterminate Western blot or a recent illness indicating seroconversion is used to estimate whether an infection occurred within 40 days of these observations. In cases when the back-projected estimated date of infection occurs prior to the last negative HIV test result, a random (uniform) time between the last negative date and the date of HIV diagnosis was selected.
Estimating incidence of currently undiagnosed infections
The back-projection of diagnoses to incidence allows estimation of a range in the date of infection of already diagnosed infections. However, the majority of infections occurring in 2013 remained undiagnosed by the end of 2013. Hence, to determine the total incidence, numbers of undiagnosed infections need to be estimated. To estimate the number of incident but undiagnosed cases, the model first pools the results for the estimated times between infection and diagnosis (up to 20 years) for diagnoses over the final 5 years of diagnoses data for sampling (the model uses this pool for all intervals). It applies this distribution of duration of time from infection to diagnosis to infer the extent of undiagnosed cases. A detailed description of the resampling method is provided in the Appendix Section 8 (http://links.lww.com/QAD/ A690).
Uncertainty
The simulation produces a distribution for the time between infection and diagnosis to incorporate the uncertainty associated with CD4 þ measurements and declines. The approach also includes variability in CD4 þ cell counts for uninfected individuals [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , uncertainty in the decline in CD4 þ cell count during primary infection [34, 44, 46, 50] , uncertainty in the mean rate of decline in CD4 þ cell counts [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] , variability in individual rates of CD4 þ decline [42] , and variability of individual CD4 þ cell counts with repeat measurement [49] . Appendix 1 (http://links.lww.com/QAD/A690) provides further information on the methodology, simulation parameter values, and uncertainty ranges. Throughout this study, the 95% uncertainty bound is the result produced by, or used in, the model in which the central 95% of results lie. This methodology was implemented in MATLAB and the source code is publicly available [51] .
Results
In Fig. 1 that while the representation of the CD4 þ declines in Fig. 1b are relatively smooth, these are summary statistics of the population. The CD4 þ cell count for an individual in the simulation can vary greatly with time and would appear much less smooth.
The CD4
þ cell count at diagnosis depends on both the time since infection and the annual probability of testing (and thus being diagnosed). This means the median time for the CD4 þ cell count of an untreated person to reach 200 cells/ml (7.0 years; Fig. 1b) is different from the time between infection and diagnosis for a person with a CD4 þ cell count of 200 cells/ml (5.0 years; Fig. 2 ), because the CD4 þ cell count at diagnosis depends on both the time since infection and the annual probability of diagnosis (i.e. testing). For example, a person who starts with a CD4 þ cell count of 1100 cells/ml will take longer, on average, to reach a CD4 þ cell count of 200 cells/ml than a person who starts with a CD4 þ cell count of 700 cells/ml. The individual with 1100 cells/ml has more opportunities for testing prior to reaching 200 cells/ml and hence is less likely to reach 200 cells/ml. In Australia, the median estimated time between infection and diagnosis in 2013 was 2.0 (IQR 0.9-3.6) years for diagnoses with CD4 þ cell counts of 500 cells/ml at diagnosis, 2.8 (IQR: 1.4-4.7) years for 350 cells/ml, and 4.5 (IQR: 2.9-6.6) years for 200 cells/ml (Fig. 2) . The distribution of time until diagnosis in Fig. 2 is specific to Australia in 2013.
The estimated number of cases diagnosed in 2013 in which their infection also occurred in 2013 was 350 (95% uncertainty bound 331-377) (Fig. 3a) . In Fig. 3b , the combined estimates of currently diagnosed and undiagnosed infections are presented. The peak of infections [1384 (95% uncertainty bound 1251-1647)] is estimated to have occurred in 1984, at a level that is lower than the peak in diagnoses (2145) in 1987. This is due to a backlog of undiagnosed infections prior to the discovery of HIV and the availability of HIV-diagnostic testing. Following this peak, the estimated number of infections reached a low of 627 (95% uncertainty bound 586-677) in 1997.
In recent years, the trend and magnitude in diagnoses are estimated to reflect incidence, but with a slight lag (Fig. 3b ). There were an estimated 912 (95% uncertainty bound 835-1002) infections in 2013, slightly less than the 938 estimated diagnosed cases. The high uncertainty in the incidence extrapolation is due to the small number of back-projected cases available in recent years. Future diagnosis data will be necessary to reduce the uncertainty regarding the number of infections in 2013. Since the HIV epidemic in Australia is predominantly driven by MSM, we separately conducted incidence back-estimates, disaggregating the total data into cases attributable to male homosexual exposure and other cases. an estimated 2281 (95% uncertainty bound 1900-2454) people were living with undiagnosed HIV. We estimate that there are 24 359 people living with currently diagnosed HIV, using a method described previously [52] ; this corresponds to 9.4% (95% uncertainty bound 7.8-10.1%) of PLHIV being undiagnosed overall, consisting of 7.9% (6.4-9.5%) for MSM and 10.7% (8.9-12.8%) for non-MSM.
The annual probability of testing for undiagnosed PLHIV in Australia is estimated to have stayed relatively constant over time (Fig. 5a) (Fig. 5b) . This reflects the reported increase in CD4 þ cell count at diagnosis over time (see Appendix Fig. A2 , http://links.lww.com/QAD/A690). However, the mean time between infection and diagnosis was 2.4 (95% uncertainty bound 2.0-3.0) years in 2013; the right skew of this distribution indicates some people are undiagnosed for longer periods. The mean time between infection and diagnosis was estimated to differ by population group in Australia: 2.0 (1.7-2.5) years in 2013 for MSM and 3.5 (2.9-4.4) years for non-MSM.
Discussion
Our CD4 þ -based back-projection methodology translates surveillance registries recording information on HIV-diagnosed cases into estimates of numbers of new infections by year, size of the undiagnosed population, annual probability of testing, and distributions in the time between infection and diagnosis. An advantage of the methodology is that it gives a distribution of expected times between infection and diagnosis for each person's CD4 þ , not simply an aggregate estimate of incidence.
Using CD4 þ cell counts to estimate time between infection and diagnosis produces relatively large uncertainty bounds as our method captures the large variability in CD4
þ cell count between and within individuals. The wide error bounds for 2013 incidence are indicative of this intrinsic uncertainty. Given further data for the following years, the error bounds for 2013 will reduce substantially as the data from 2014 and later years will inform the size of the undiagnosed population in 2013. This methodology demonstrates the substantial difference in the trends in incidence between MSM and those who are not MSM, with a substantial growth in incidence in MSM followed by a decrease in the 1980s. We estimate that there has been a steady increase in the incidence of HIV from 1985 onwards among non-MSM in Australia.
The choice of median CD4 þ cell count following the primary infection (peak of CD4 þ rebound level) and the method's structural assumption of a square root decline influences the outcome of time between infection and diagnosis and hence all results in the model (as demonstrated in section 12 of the Appendix, http:// links.lww.com/QAD/A690). There is also a large degree of uncertainty in these key parameters but our model incorporates the range of values obtained from multiple studies in order to produce results reflective of this uncertainty (see Appendix sections 3, 4, and 5, http:// links.lww.com/QAD/A690). However, our approach ignores environmental or other factors, which can affect CD4 þ cell count. For example, CD4 þ cell count may be affected by smoking [53] and CD4 þ decline may be affected by previous intravenous drug use [54] .
Differences in CD4
þ cell counts and declines by age [55] and between sexes [56] are not taken into account in this model. The population of PLHIV in Australia is overwhelmingly men, which is in alignment with the majority of studies used to source parameters for this study. Therefore, the results reported in this study should not be heavily affected by this limitation, but an analysis of the incidence in women only may require an adjustment of parameters used in the model.
The lack of testing prior to 1983 causes the interaction of testing rate and CD4 þ cell count during the optimization phase to be unconstrained, increasing the uncertainty in results. The uncertainty bounds of the incidence curve in the early 1980s and 1970s only represent the uncertainty in the numerical calculations, and do not incorporate the uncertainty associated with the limitations of the model for this period (Fig. 3) . As CD4 þ cell count was not reported routinely during the early stages of the epidemic, many records required an imputed CD4 þ cell count (93% of cases prior to 1990). This may skew our results for earlier years as CD4 þ cell counts were likely collected more often from those who showed signs of immunosuppression. Additionally, imputation may decrease the uncertainty in the data for earlier years and hence present uncertainty bounds that are smaller than expected, given the limited data.
Early back-projection models relied on progression to AIDS in blood recipients [3] that may not be representative of the majority of the population with HIV, given the high degree of variability of CD4 þ cell counts and dependence of progression to AIDS based on both lifestyle [57] and age [58] . Models that rely heavily on AIDS diagnosis as a determinant of time between infection and diagnosis [5, 8, 9] have become less relevant as AIDS becomes rarer, especially in high-income countries, due to earlier testing and initiation of effective ART.
Estimates for HIV incidence in Australia have previously been made using a modified back-projection method that combines HIV diagnosis, AIDS diagnosis, and recent infection information [59] . This method was used to estimate incidence by age cohort [60] , subpopulation category (MSM, heterosexual, people who inject drugs) [61] , and Australian state and territory [62] , and relies on AIDS diagnoses and recent diagnosis data to inform the calculation of an incidence estimate. We believe that our new method offers an improvement on this method as we consider CD4 þ at diagnosis in addition to recent infection.
A simple approach using CD4 þ cell count around diagnosis can be useful for assessing trends in early versus late diagnosis. Previously, simplified CD4 þ -based methods have been used by us in policy forums and others (e.g. [12] ) to estimate the average time from infection to diagnosis. For example, by assuming that the median CD4 þ cell count for someone without HIV is 891 cells/ml, approximately 25-30% of cells are lost in the first year of infection and $60 cells/ml are lost per year thereafter (until a CD4 þ cell count of 200 cells/ml) then an average time from infection to diagnosis can be estimated based on the average CD4 þ cell count of newly diagnosed cases. In Australia, the median CD4 þ cell count at diagnosis in 2009-2013 was $450 cells/ml, leading to an estimated average time from infection to diagnosis of $4.5 years. The method we present in this paper yields substantially lower estimates, namely, 2.4 years as a mean and 0.9 years as a median. There are two main reasons for this difference. Firstly, the rate at which people at risk of HIV are tested in a population influences the population average time from infection to particular CD4 þ levels. This creates a selection bias; for example, in a population in which testing rates are typically high, if someone is diagnosed with a low CD4 þ cell count it is more likely that this person has a lower baseline CD4
þ cell count prior to infection than them arriving at that CD4 þ cell count after an extended period of infection. Secondly, the rate of CD4 þ decline averages around 60 cells/ml per year during the overall course of natural infection but is greater initially and slower later in infection. Our current method incorporated the statistical distribution in starting CD4
þ cell counts and decline rates across the population. It also inferred a time-dependent testing rate to match a simulated distribution of CD4 þ cell counts at diagnosis with the observed distribution of CD4 þ cell counts at diagnosis. Additionally, our current method incorporates separate information about diagnosed cases which have evidence of recent infection. These adjustments account for the majority of the difference in magnitude of estimates in time from infection to diagnosis. Both approaches provide consistent time trends in the duration of infection prior to diagnosis. We believe that our new method provides a more accurate estimate of the average time between infection and diagnosis. However, this is subject to future validation. The range of estimates across methods suggests that currently there remains a lack of precision for estimating the magnitude of this indicator.
The number of diagnoses is not adjusted for underreporting in this study because we believe that available records are representative of the total diagnoses in Australia. HIV is a notifiable infection in Australia, which means new diagnoses must be reported to the relevant state authority. Additionally, subsequent adjustment of total reported diagnoses in later years have been low (<2% increase). Although we believe adjustment for underreporting and delayed notification is unnecessary in Australia, such an adjustment may be necessary in other locations.
Our method may provide an improvement for estimating HIV incidence and the time between infection and diagnosis from routinely collected diagnosis data, or at least provide supplemental information on existing approaches. This is useful for understanding the current and future direction of HIV epidemics and the likely impact of HIV interventions and public health policy.
